-
公开(公告)号：US11053225B2
公开(公告)日：2021-07-06
申请号：US16610327
申请日：2018-05-02
Inventor： Sung Yun Cho , Chang Hoon Lee , Yong Ki Min , Jong Yeon Hwang
IPC: C07D401/14 , C07D403/04 , A61K31/506 , C07D403/14 , C07D239/48 , C07D405/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: A pyrimidine derivative compound of Chemical Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a composition for preventing or treating cancer comprising the same as an active ingredient. The pyrimidine derivative compound of Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof has an excellent selective inhibitory effect especially against TYRO 3 among TAM receptor inhibitory effects, and thus can be used as an excellent composition of preventing or treating cancer without adverse effects resulting from the inhibition of Axl and Mer.
-
公开(公告)号：US11192878B2
公开(公告)日：2021-12-07
申请号：US16609805
申请日：2018-05-11
Inventor： Jong Yeon Hwang , Jae Du Ha , Sung Yun Cho , Pil Ho Kim , Chang Soo Yun , Chi Hoon Park , Chong Ock Lee , Sang Un Choi , Joo Youn Lee , Sunjoo Ahn
IPC: C07D401/04 , A61P35/00 , C07D401/14
Abstract: The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.
-
公开(公告)号：US11084824B2
公开(公告)日：2021-08-10
申请号：US16612592
申请日：2018-05-14
Inventor： Pilho Kim , Sung Yun Cho , Jae Du Ha , Hyoung Rae Kim , Jong Yeon Hwang , Chang Soo Yun , Hee Jung Jung , Chi Hoon Park , Chong Ock Lee , Chang Hoon Lee , Sunjoo Ahn
IPC: A61K31/519 , A61P25/16 , A61P35/00 , A61P37/00 , C07D487/04 , A23L33/10
Abstract: The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.
-
Patent Agency Ranking
公开(公告)号：US20180111905A1
公开(公告)日：2018-04-26
申请号：US15565897
申请日：2016-04-06
Inventor： Pilho Kim , Hyoung Rae Kim , Sung Yun Cho , Jae Du Ha , Hee Jung Jung , Chang Soo Yun , Jong Yeon Hwang , Chi Hoon Park , Chong Ock Lee , Sunjoo Ahn , Chong Hak Chae
IPC: C07D239/48 , A61P35/00 , C07D401/12 , C07D403/12 , A23L33/00 , A23L33/10
CPC classification number: C07D239/48 , A23L33/10 , A23L33/30 , A23L33/40 , A23V2002/00 , A61K31/505 , A61P35/00 , C07D401/12 , C07D403/12
Abstract: The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
-
公开(公告)号：US10369149B2
公开(公告)日：2019-08-06
申请号：US15567224
申请日：2015-12-30
Inventor： Jong Yeon Hwang , Hyoung Rae Kim , Jae Du Ha , Sung Yun Cho , Hee Jung Jung , Pilho Kim , Chang Soo Yun , Chong Ock Lee , Chi Hoon Park , Chong Hak Chae , Sunjoo Ahn
IPC: A61K31/506 , C07D239/30 , C07D239/48 , A23L33/10 , A61P35/00 , C07B43/04 , C07C13/48
Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
-
公开(公告)号：US10100019B2
公开(公告)日：2018-10-16
申请号：US15565897
申请日：2016-04-06
Inventor： Pilho Kim , Hyoung Rae Kim , Sung Yun Cho , Jae Du Ha , Hee Jung Jung , Chang Soo Yun , Jong Yeon Hwang , Chi Hoon Park , Chong Ock Lee , Sunjoo Ahn , Chong Hak Chae
IPC: C07D239/48 , A61K31/505 , A61P35/00 , A23L33/10 , A23L33/00 , C07D401/12 , C07D403/12
Abstract: The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
-
公开(公告)号：US12161722B2
公开(公告)日：2024-12-10
申请号：US18573904
申请日：2022-06-24
Inventor： Pil Ho Kim , Sung Yun Cho , Jae Du Ha , Chi Hoon Park , Jong Yeon Hwang , Hyun Jin Kim , Song Hee Lee , Ye Seul Lim , Han Wool Kim , Sun Mi Yoo , Beom Seon Suh , Ji Youn Park , Je Ho Ryu , Jung Min Ahn , Hee Jung Moon , Ho Hyun Lee
Abstract: The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
-
公开(公告)号：US10053458B2
公开(公告)日：2018-08-21
申请号：US15319151
申请日：2015-05-21
Inventor： Chang Soo Yun , Hyoung Rae Kim , Sung Yun Cho , Hee Jung Jung , Kwangho Lee , Chong Hak Chae , Chong Ock Lee , Chi Hoon Park , Pilho Kim , Jong Yeon Hwang , Jae Du Ha , Sun Joo Ahn
IPC: C07D471/04 , C07D405/14 , C07D401/14 , C07D403/12 , C07D401/12
CPC classification number: C07D471/04 , A61K31/506 , C07D209/04 , C07D239/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14
Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.093 seconds)
